Cetuximab for recurrent and/or metastatic squamous cell carcinoma of the head and neck: A nice single technology appraisal

PharmacoEconomics

Volumn 28, Issue 6, 2010, Pages 439-448

  Bagust, Adrian ^a   Greenhalgh, Janette ^a   Boland, Angela ^a   Fleeman, Nigel ^a   McLeod, Claire ^a   Dickson, Rumona ^a   Dundar, Yenal ^a   Proudlove, Christine ^b   Shaw, Richard ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b North West Medicines Information Centre Liverpool ^*  (United Kingdom)

Author keywords

Cetuximab; Cost utility; Formularies; Head and neck cancer; Squamous cell cancer; Therapeutic use; Treatment

Indexed keywords

CARBOPLATIN; CETUXIMAB; CISPLATIN; FLUOROURACIL;

ACCURACY; ACNE; ACNEIFORM DERMATITIS; AGE DISTRIBUTION; BODY SURFACE; CANCER CONTROL; CANCER GROWTH; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DERMATITIS; DRUG COST; DRUG EFFECT; DRUG MANUFACTURE; DRUG SAFETY; DRUG TREATMENT FAILURE; ECONOMIC EVALUATION; EVIDENCE BASED MEDICINE; HEAD AND NECK CARCINOMA; HEALTH ECONOMICS; HEALTH STATUS; HUMAN; KARNOFSKY PERFORMANCE STATUS; LIFE EXPECTANCY; METASTASIS; MODEL; MOUTH CARCINOMA; NATIONAL HEALTH ORGANIZATION; OVERALL SURVIVAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROBABILITY; PROGNOSIS; PROGRESSION FREE SURVIVAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RECURRENT CANCER; RELIABILITY; REVIEW; SEX DIFFERENCE; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME; TREATMENT RESPONSE; UNITED KINGDOM;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, SQUAMOUS CELL; CISPLATIN; COST-BENEFIT ANALYSIS; DRUG UTILIZATION REVIEW; HEAD AND NECK NEOPLASMS; HEALTH CARE COSTS; HUMANS; NEOPLASM METASTASIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE;

EID: 77952570160     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.2165/11532220-000000000-00000     Document Type: Review

References (14)

1. National Institute for Health and Clinical Excellence. Guide to the single technology appraisal (STA) process. London: Nice, 2006 Sep. [online]. Available from URL: Http://Www.nice.org.uk/media/8DE/74/STA-Process-Guidepdf [Accessed 2009 Jun. 10]
2. National Institute for Health and Clinical Excellence. Head and neck cancer (squamous cell carcinoma) - cetuximab. London: Nice [online]. Available from URL: Http://Www.nice.org.uk/guidance/index.jsp?action=byId&o= 11987&his tory=t [Accessed 2010 Feb. 2]
3. Office of National Statistics. Cancer statistics registrations: Registrations of cancer diagnosed in 2005, England [series MB1 no. 36]. Norwich: Office of National Statistics, 2008 [online]. Available from URL: Http://Www.statistics.gov. uk/downloads/theme-health/MB1-36/MB1-No36-2005pdf [Accessed 2008 Oct. 1]
4. Welsh Cancer Intelligence and Surveillance Unit. Cancer incidence in Wales 2002-2006 [WCISU annual publication no. SA8/01; online]. Available from URL: Http://Www.wales.nhs.uk/sites3/Documents/242/incpub2006%5F31Jan08pdf [Accessed 2008 Oct. 1]
5. Dobrossy L. Epidemiology of head and neck cancer: Magnitude of the problem. Canc Metastasis Rev 2005;24(1):9-17
6. National Institute for Health and Clinical Excellence. Cetuximab for the treatment of locally advanced squamous cell cancer of the head and neck [NICE technology appraisal guidance 145]. London: Nice, 2008 [online]. Available from URL: Http://Www.nice.org.uk/guidance/index.jsp?action=download&o=41000 [Accessed 2008 Oct. 1]
7. European Medicines Agency. Committee for Medicinal Products for Human Use post-authorisation summary of positive opinion for erbitux. London: European Medicines Agency, 2008 [online]. Available from URL: Http://Www.emea.europa.eu/ pdfs/human/opinion/Erbitux-56158008enpdf [Accessed 2009 Jun. 10]
8. ® (Cetuximab) for the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck [online]. Available from URL: Http://Www.nice.org.uk/ nicemedia/pdf/MerckSeronopdf [Accessed 2009 Jun. 10]
9. Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008 Sept; 359:1116-27
10. ® (Cetuximab) for the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck [online]. Available from URL: Http://Www.nice.org.uk/nicemedia/pdf/MerckSeronopdf [Accessed 2009 Jun. 10]
11. Kind P. Measuring the value of quality of life in cancer: An index based on EORTC QLQC-30 [abstract]. J Clin Oncol 2005;23(16S): 6013
12. Sacco JJ, Botten J, Macbeth F, et al. The average body surface area of adult cancer patients in the UK: A multicentre retrospective study. PloS ONE 2010;5(1):E8933
13. National Institute for Health and Clinical Excellence. Final appraisal determination: Cetuximab for the treatment of recurrent and/or metastatic squamous cell cancer of the head and neck. London: Nice, 2009 Apr. [online]. Available from URL: Http://Www.nice.org.uk/nicemedia/pdf/ SquamousCellCarcinomaCetuximabFADpdf [Accessed 2009 Jun. 10]
14. National Institute for Health and Clinical Excellence. Appraising life-extending end of life treatments. London: Nice, 2009 Jan [online]. Available from URL: Http://Www.nice.org.uk/media/88A/F2/ SupplementaryAdviceTACEoLpdf [Accessed 2009 Jun. 10]